Last reviewed · How we verify
BXT-51072
BXT-51072 is a small molecule inhibitor of the SGLT2 receptor.
BXT-51072 is a small molecule inhibitor of the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | BXT-51072 |
|---|---|
| Sponsor | Synvista Therapeutics, Inc |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 2 |
Mechanism of action
By inhibiting the SGLT2 receptor, BXT-51072 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This mechanism is similar to other SGLT2 inhibitors, which have been shown to be effective in treating type 2 diabetes. BXT-51072 is being investigated for its potential to improve glycemic control in patients with type 2 diabetes.
Approved indications
- Type 2 diabetes
Common side effects
- Increased risk of diabetic ketoacidosis
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BXT-51072 CI brief — competitive landscape report
- BXT-51072 updates RSS · CI watch RSS
- Synvista Therapeutics, Inc portfolio CI